Interventional procedures

Limitations are obvious if the diseased tissue does not differ from normal tissue or successfully treated tissue in respect of the above-mentioned criteria. Under these conditions, even a contrast agent with high absorption of X-rays is of no help. Another drawback is the short-lasting contrast which requires repeated injections if the diagnosis is missed during the first scan or if persistent visualization of a lesion is required during an interventional procedure. 

Another method for reducing osmolality of the injection was achieved by the synthesis of mono-carboxylic dimers, leading to the development of ioxaglic acid (600 mOsm kg at 320 mgl mL ). Because of specific properties on platelet functions and thrombin generation, this agent is widely used for interventional procedures [3]. 

By 1996 over 500,000 coronary interventions were performed annually, which has more than doubled to today s current standard. These pioneers have paved the way for interventional procedures that now serve as the standard of care for symptomatic coronary artery disease. While coronary intervention remains in its adolescent stage, the quality of care has increased substantially and the bar is ever increasing as to the extent coronary interventions play in our society s healthcare. 

In July 2003, TandemHeart received 510(k) approval from the FDA for short-term (up to 6 h) use in refractory cardiogenic shock. Subsequently, the duration of use was extended up to 3 weeks. It is also being evaluated as a bridge to long-term ventricular assistance and as a means of cardiac support in high-risk interventional procedures [22]. 

Clinical staff taking part in diagnostic and interventional procedures using fluoroscopy wear protective aprons to shield internal tissues and organs in the torso from scattered x rays. Use of the measurements from monitoring devices worn outside and above protective aprons as the record of or E for these individuals results in significant overestimates of their actual risk. 

Platelet glycoprotein Ilb/llla (GPIIb/llla) receptor inhibitors are widely used to prevent thrombotic vascular events, especially in patients with acute coronary syndromes (ACS) or in those undergoing intravascular interventional procedures. The purpose of this chapter is to evaluate the quality and magnitude of the clinical trial evidence in support of their use, In addition, key issues regarding their optimal application in clinical practice will be discussed. 

When BP control is needed during interventional procedures, one can use intravenous nitrates or combined alpha-beta blockers such as labetalol. When these agents fail,... 

Acute vessel recoil, chronic remodeling, and intimal hyperplasia were the mechanisms involved in this process (1-4). However, after the introduction of stents in the daily practice during interventional procedures, intimal hyperplasia became the mechanism associated in the pathophysiology of in-stent restenosis (5-9). Therefore, its prevention should be related with therapies that inhibit smooth muscle cell proliferation. 

Today, standard therapy for myocardial infarction or luminal narrowing includes thrombolytics, anticoagulants, and often interventional procedures such as PTCA. With its introduction... 

With proper pharmacotherapy and optimization of overall clinical status, most patients will be able to overcome the problem of orthopnea for the duration of interventional procedure. Diuretic therapy preintervention may be useful. In the very ill patient with hemodynamic compromise, and where intervention may lead to an improvement in cardiac function, supportive measure, such as intra-aortic balloon counterpulsation, pressure monitoring, or ventilation may be necessary during the acute phase of the illness. 

Epilogue Anticoagulant management of patients undergoing interventional procedures... 

I am pleased to write this introduction for the Textbook of Interventional Cardiovascular Pharmacology. This definitive international textbook on cardiovascular pharmacology for interventional procedures incorporates contributions from world opinion leaders and a transatlantic perspective. This textbook is a first of its kind for practicing interventional cardiologists, cardiologists, and pharmacologists. 

Recidivation is generally due to undetected small intra-hepatic foci. Especially in cirrhosis, the recurrence rate is very high as a result of this factor. A further cause of recidivation after primary RO resection is attributed to the multicentricity of the HCC, i. e. synchronic or metachronic development of additional tumours which are independent of the primary tumour. Therefore, the secondary prophylaxis takes on a special meaning (systemic or intra-arterial chemotherapy, interferon, retinoids, autologous lymphocyte transfusion, etc.). An increase in ornithine decarboxylase and spermidine is apparently a high risk factor for recurrence. Even after recidivation, repeated resection or interventional procedures (e.g. RFTA) are sometimes successful. 

After discussing the clinical and imaging findings as well as the result of exploratory laparoscopy, it is important to decide on the most promising management in the interdisciplinary conference. Once resection techniques and liver transplantation have been ruled out, the next alternative are interventional procedures (s. tab. 37.9). 

Combination therapy The use of local-interventional procedures is restricted to a maximum tumour size of 5 cm in diameter. Therefore, a combination of two local techniques is seen as promising. The joint application of PEI and TAB has proved its efficacy for some time. (177) Similarly, there have been reports about the successful use of TACE following laser thermal ablation. (136) Further encouraging options include a combination of TACE and RFTA, TACE with microwave coagulation (149) or TACE with cryotherapy. Using TACE, the size of the HCC can be reduced in some cases, making it possible to carry out subsequent ablation with better results. 

There are no clear recommendations concerning indications for percutaneous interventional procedures. It is uncertain whether the metastases have been completely removed when guiding is based on imaging techniques. Moreover, the extent of the placed necrosis can only be assessed in a limited way however, evaluation is more exact if the resected tissue is analyzed histologically. 

Kaufman JA, Geller SC, Waltman AC. Renal insufficiency gadopentetate dimeglumine as a radiographic contrast agent during peripheral vascular interventional procedures. Radiology 1996 198 579-581. 

HatrickAG, JaroszJM, Irvine AT. Gadopentate dimeglumine as an alternative contrast agent for use in interventional procedures. Clin Radiology 1997 52 948-952. 

---